Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Professor Jane Armitage, Professor of Clinical Trials and Epidemiology, was recognised in the New Year’s Honours list, published on 29 December. Jane was appointed Officer of the Order of the British Empire (OBE) in recognition of her services to medical research. 

The New Year’s Honours list recognises outstanding achievements by a wide range of extraordinary people from across the United Kingdom. People are awarded honours for achievements in their field of work (including health, education, science and technology), as well as for making a difference to their community.

Professor Armitage joined the Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU), now part of NDPH, in 1990. She has co-ordinated and been Principal Investigator of a number of our major randomised clinical trials in cardiovascular disease, including the MRC/BHF Heart Protection Study, SEARCH (Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine), HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events) and ASCEND (A Study of Cardiovascular Events in Diabetes).

In addition to her work on clinical trials, Jane has undertaken valuable roles in the Department (for example, as its Director of Training & Career Development and as a programme leader for our MRC Population Health Research Unit), as well as acting as a member of a number of external Steering Committees and Grant Review Committees, and as an Honorary Consultant in Public Health Medicine.

Professor Sir Rory Collins, Head of the Nuffield Department of Population Health, said: “Jane is well-known and highly respected within the research community both nationally and internationally, and I’m absolutely delighted that her significant achievements have been recognised by this honour. Her OBE is very well-deserved, and it is a due recognition of her sustained contribution to improving the lives of those suffering from, or at risk of, cardiovascular disease.”

Professor Armitage is one of six members of the University of Oxford to be honoured this year.

Similar stories

Travels with Vignesh

CRM General

Vignesh Murugesan, a Postdoctoral Researcher in Department of Physiology, Anatomy & Genetics (DPAG), describes how he found his way from the large metropolitan town of Chennai in India to studying regenerative medicine here in Oxford, via an 8 year stint in Sweden.

Genetic breakthrough to target care for deadly heart condition

CRE Research

Professor Watkins and his team have found a new type of genetic change in the DNA of people with hypertrophic cardiomyopathy (HCM) - a silent killer amongst families that can cause sudden death in young people due to the thickening of the heart muscle.

Earliest origins of the forming heart identified

CRE Research

The earliest known progenitor of the outermost layer of the heart has been characterised for the first time and linked to the development of other critical cell types in the developing heart in a new paper from the Srinivas group led by BHF Immediate Fellow Dr Richard Tyser.

Professor Sir Rory Collins awarded the MRC Millennium Medal 2020

CRE Research

Professor Sir Rory Collins, Head of the Nuffield Department of Population Health, and Principal Investigator and Chief Executive of UK Biobank, has been awarded the Medical Research Council (MRC) Millennium Medal 2020, the MRC’s most prestigious personal award.

New MRI technique could detect early signs of heart failure in cancer patients following chemotherapy

CRE Publication Research

New research led by Oxford BHF CRE Intermediate Transition Fellow Dr Kerstin Timm shows that a recently developed imaging technique pioneered by the Tyler Group can detect early metabolic changes in the heart caused by a commonly used chemotherapy drug, which is known to increase risk of heart failure in cancer survivors.